For example, a patient with metastatic NSCLC with PD‐L1 expression levels ≥1% and a targetable driver oncogene is more appropriately treated with first‐line oncogene‐driven therapy rather than immunotherapy‐based treatment. Here, CD274 is linked to non-small cell lung carcinoma.